表紙
市場調查報告書

纖維症:全球臨床實驗趨勢

Fibrosis Global Clinical Trials Review, H2, 2019

出版商 GlobalData 商品編碼 346013
出版日期 內容資訊 英文 187 Pages
訂單完成後即時交付
價格
纖維症:全球臨床實驗趨勢 Fibrosis Global Clinical Trials Review, H2, 2019
出版日期: 2019年12月16日內容資訊: 英文 187 Pages
簡介

本報告提供纖維症臨床實驗相關之最新趨勢分析,提供您各地區主要國家的臨床實驗數量,臨床實驗的各階段進展,實驗對象採用狀況彙整有潛力的贊助商,各企業和研究機關的研究進展,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美的主要國家的臨床實驗數量
    • 中東·非洲的主要國家的臨床實驗數量
    • 中南美的主要國家的臨床實驗數量

G7各國臨床實驗數量:肌肉骨骼系統疾病治療藥臨床實驗上纖維症所佔的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:肌肉骨骼系統疾病治療藥臨床實驗上纖維症所佔的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

纖維症治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC5201CTIDB

GlobalData's clinical trial report, "Fibrosis Global Clinical Trials Review, H2, 2019" provides an overview of Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials 22
  • Clinical Trials by Phase in E7 Countries 24
  • Clinical Trials in E7 Countries by Trial Status 25
  • Clinical Trials by Phase 26
  • In Progress Trials by Phase 27
  • Clinical Trials by Trial Status 28
  • Clinical Trials by End Point Status 30
  • Subjects Recruited Over a Period of Time 31
  • Clinical Trials by Sponsor Type 32
  • Prominent Sponsors 33
  • Top Companies Participating in Fibrosis Therapeutics Clinical Trials 35
  • Prominent Drugs 36
  • Latest Clinical Trials News on Fibrosis 37
  • Nov 08, 2019: Forbius completes phase 1 oncology dose-escalation with AVID200, first-in-class TGF-beta 1 & 3 inhibitor: Well tolerated, target inhibition demonstrated at all dose levels, data reported at SITC 37
  • Oct 31, 2019: Galmed Pharmaceuticals to present new data on aramchol effect on glucose metabolism, MoA and clinical results at AASLD 2019 37
  • Oct 14, 2019: Forbius completes enrollment into phase 1a solid tumor trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing 38
  • Oct 10, 2019: Can Fite announces publication of Namodenoson NASH mechanism of action in International Journal of Molecular Medicine 38
  • Sep 26, 2019: Galmed Pharmaceuticals initiated ARMOR, a phase 3/4 registrational study of Aramchol in subjects with NASH and fibrosis 38
  • Clinical Trial Profile Snapshots 40

Appendix 188

  • Abbreviations 188
  • Definitions 188
  • Research Methodology 189
  • Secondary Research 189
  • About GlobalData 190
  • Contact Us 190
  • Source 191

List of Tables

  • Fibrosis Therapeutics, Global, Clinical Trials by Region, 2019* 8
  • Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
  • Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
  • Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
  • Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
  • Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
  • Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15
  • Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
  • Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2019* 18
  • Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
  • Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 21
  • Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2019* 23
  • Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
  • Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
  • Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2019* 26
  • Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 27
  • Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29
  • Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30
  • Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31
  • Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 32
  • Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34
  • Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35
  • Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 36

List of Figures

  • Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
  • Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
  • Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
  • Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
  • Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
  • Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
  • Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15
  • Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
  • Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2019* 17
  • Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
  • Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
  • Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2019* 22
  • Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
  • Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
  • Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26
  • Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 27
  • Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28
  • Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30
  • Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31
  • Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 32
  • Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33
  • Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35
  • Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 36
  • GlobalData Methodology 189